We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
EFFICACY OF INTRA-ARTERIAL LIDOCAINE FOR PAIN CONTROL RESULTING FROM TRANSARTERIAL CHEMOEMBOLIZATION OF HEPATOCELLULAR CARCINOMA.
- Authors
Abbas, Ghulam; Sheraz, Atif; Rahim, Raza
- Abstract
Objective: To assess the efficacy of intra-arterial lidocaine in peri & post-procedural pain control and the dose of narcotic analgesic required in hepatocellular carcinoma patients undergoing transarterial chemoembolization. Study Design: Comparative prospective study. Place and Duration of Study: Armed Forces Institute of Radiology and Imaging Rawalpindi, from Jan to Jun 2019. Methodology: A total of 60 patients included in this study where 42 males and 18 were females, age range 45-85 years who underwent transarterial chemoembolization for hepatocellular carcinoma, were included in the study. patients were equally divided into two groups, group a (30 patients) who underwent transarterial chemoembolization, received 60 mg of intraarterial lidocaine each and group b (30 patients) who underwent transarterial chemoembolization, intra-arterial lidocaine was substituted with normal saline.degree of post-procedural pain was assessed using a subjective method (visual analogue scales score) and an objective method (amount of post-procedural analgesics). Results: Average peri-procedure visual analogue scale score was 5.06 in group A patient versus 7.2 for those in group B patients (p=0.037). Post-procedure visual analogue scale score in the group A was 2.7 ± 0.520 and that for group B was 4.2 ± 0.761 (p=0.025). Mean of total dose of nalbuphine in group A was 4.96 ± 0.764 mg versus 8.3 ± 1.34 mg for patients in group B (p=0.036). Average length of post procedure hospital stay was 0.9 ± 0.203 and 1.41 ± 0.373 days for group A and group B respectively (p=0.002). Conclusion: Intra-arterial administration of lidocaine before infusing the embolization particles for transarterial chemoembolization in patients with hepatocellular carcinoma is safe and effective in doses as low as 50 mg for reducing peri & postprocedural pain and reducing dosage of narcotic analgesics.
- Subjects
CHEMOEMBOLIZATION; PAIN management; HEPATOCELLULAR carcinoma; VISUAL analog scale; LIDOCAINE; NALBUPHINE; ANALGESICS
- Publication
Pakistan Armed Forces Medical Journal, 2021, Vol 71, Issue 3, p910
- ISSN
0030-9648
- Publication type
Article
- DOI
10.51253/pafmj.v71i3.4843